Materiały źródłowe

• #1 Granulomatosis with polyangiitis – Symptoms and causes – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/granulomatosis-with-polyangiitis/symptoms-causes/syc-20351088

  It’s important for healthcare professionals to find and treat GPA as soon as possible. Early treatment can help people live full lives. Without treatment, the condition can lead to organ damage that sometimes is fatal. […] The disease can become worse quickly. Without treatment, it can lead to other serious health conditions called complications. That’s why it’s important for a healthcare professional to find it and start treatment early.

• #2 Granulomatosis with Polyangiitis (GPA, formerly Wegener Granulomatosis) Treatment & Management: Approach Considerations, Remission Induction, Remission Maintenance

  https://emedicine.medscape.com/article/332622-treatment

  The mainstay of treatment for granulomatosis with polyangiitis (GPA) is a combination of corticosteroids and cytotoxic agents. Treatment should be tailored to appropriately treat GPA manifestations while minimizing long-term toxicities to the patient. Untreated generalized or severe GPA typically carries a dismal prognosis, with up to 90% of patients dying within 2 years, usually of respiratory or kidney failure. Even non-renal GPA carries a mortality rate of up to 40%. […] Outcomes for this previously fatal disease improved dramatically with the introduction in the 1970s of cyclophosphamide, which was administered in combination with corticosteroids. Approximately 90% of patients with GPA respond to cyclophosphamide, with approximately 75% experiencing complete remission. However, 30%-50% of those who initially respond experience at least one relapse, requiring another course of therapy.

• #3 Granulomatosis with polyangiitis and microscopic polyangiitis: Induction and maintenance therapy – UpToDate

  https://www.uptodate.com/contents/granulomatosis-with-polyangiitis-and-microscopic-polyangiitis-induction-and-maintenance-therapy

  Granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) are related systemic vasculitides that, along with eosinophilic granulomatosis with polyangiitis (Churg-Strauss), make up the antineutrophil cytoplasmic autoantibody (ANCA)-associated vasculitides. […] Therapy for GPA and MPA has two main components: induction of remission with immunosuppressive therapy and maintenance of remission with immunosuppressive therapy for a variable period to prevent relapse. […] Induction and maintenance therapy of GPA and MPA will be reviewed here.

• #4 Granulomatosis with Polyangiitis (GPA, formerly Wegener Granulomatosis) Treatment & Management: Approach Considerations, Remission Induction, Remission Maintenance

  https://emedicine.medscape.com/article/332622-treatment

  The combination of cyclophosphamide and glucocorticoids remained the recommended therapy for induction of remission in generalized/severe GPA for years. In 2011, however, the US Food and Drug Administration (FDA) approved the use of rituximab, a monoclonal antibody that targets B cells, in combination with steroids, for induction of remission in GPA (and microscopic polyangiitis). Because rituximab has been shown to be as effective as cyclophosphamide and is considered less toxic, in 2021, the American College of Rheumatology/Vasculitis Foundation guidelines conditionally recommended rituximab over cyclophosphamide for remission induction in patients with active, severe GPA. […] In general, limited disease does not require as aggressive therapy as does severe disease. Additionally, treatment recommendations are different for induction of remission and maintenance of remission.

• #5 Granulomatosis with Polyangiitis (GPA, formerly Wegener Granulomatosis) Treatment & Management: Approach Considerations, Remission Induction, Remission Maintenance

  https://emedicine.medscape.com/article/332622-treatment

  The mainstay of treatment for granulomatosis with polyangiitis (GPA) is a combination of corticosteroids and cytotoxic agents. Treatment should be tailored to appropriately treat GPA manifestations while minimizing long-term toxicities to the patient. Untreated generalized or severe GPA typically carries a dismal prognosis, with up to 90% of patients dying within 2 years, usually of respiratory or kidney failure. Even non-renal GPA carries a mortality rate of up to 40%. […] Outcomes for this previously fatal disease improved dramatically with the introduction in the 1970s of cyclophosphamide, which was administered in combination with corticosteroids. Approximately 90% of patients with GPA respond to cyclophosphamide, with approximately 75% experiencing complete remission. However, 30%-50% of those who initially respond experience at least one relapse, requiring another course of therapy.

• #6 Granulomatosis with Polyangiitis (GPA, formerly Wegener Granulomatosis) Treatment & Management: Approach Considerations, Remission Induction, Remission Maintenance

  https://emedicine.medscape.com/article/332622-treatment

  Current treatment recommendations in GPA depend on the severity and activity of disease. […] Generalized or severe disease generally requires aggressive therapy. Since introduced by Fauci et al in the 1970s, oral cyclophosphamide in combination with high-dose glucocorticoids (eg, prednisone 1 mg/kg/day) has been the criterion standard for induction of remission in AAV. […] Cyclophosphamide can be given either by a daily oral route or intermittent intravenous route in combination with high-dose glucocorticoids. […] Pulsed cyclophosphamide has been shown to be as effective as daily oral cyclophosphamide in inducing remission. […] Current guidelines suggest that in adults, the choice between oral and IV cyclophosphamide options should be based on patient and physician preferences, while in children, IV cyclophosphamide may be preferred to facilitate compliance and limit toxicity.

• #7 Granulomatosis With Polyangiitis – StatPearls – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK557827/

  The treatment of GPA involves the use of immunosuppressive agents in a variety of combinations. Treatment is classified into 2 phases: the induction phase and the maintenance phase. Commonly used agents are cyclophosphamide, glucocorticoids, rituximab, azathioprine, methotrexate, and plasmapheresis if indicated. […] The following are key points from the 2022 EULAR recommendations for managing ANCA-associated vasculitis. For new-onset organ/life-threatening GPA (and MPA), induce remission with glucocorticoids and rituximab or cyclophosphamide. Rituximab is preferred for relapsing disease. […] For new-onset non-organ/life-threatening GPA, induce remission with glucocorticoids and rituximab. In some cases, methotrexate and mycophenolate mofetil can be substituted for rituximab. Cyclophosphamide is not preferred due to increased adverse effects, although it is equally effective.

• #8 Granulomatosis With Polyangiitis (GPA, formerly Wegener’s)

  https://my.clevelandclinic.org/health/diseases/granulomatosis-with-polyangiitis-formerly-wegeners-granulomatosis

  Healthcare providers treat granulomatosis with polyangiitis (Wegeners) with anti-inflammatory and immune system-suppressing drugs (corticosteroids and other immunosuppressants). […] Initial treatment for active GPA includes: […] High doses of corticosteroids, such as prednisone. These doses will eventually taper off. […] Rituximab. This newer biologic medication is now standard treatment. […] Cyclophosphamide (for severe disease) or methotrexate (for milder disease). These drugs also treat cancer, but for GPA (at much lower doses), they function as immunosuppressants. […] Avacopan. This drug can be used as an adjuvant treatment to reduce your dosage of corticosteroids. […] If you have severe complications, you might need additional treatment, such as: […] Dialysis […] Organ transplantation.

• #9 Granulomatosis With Polyangiitis – StatPearls – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK557827/

  The treatment of GPA involves the use of immunosuppressive agents in a variety of combinations. Treatment is classified into 2 phases: the induction phase and the maintenance phase. Commonly used agents are cyclophosphamide, glucocorticoids, rituximab, azathioprine, methotrexate, and plasmapheresis if indicated. […] The following are key points from the 2022 EULAR recommendations for managing ANCA-associated vasculitis. For new-onset organ/life-threatening GPA (and MPA), induce remission with glucocorticoids and rituximab or cyclophosphamide. Rituximab is preferred for relapsing disease. […] For new-onset non-organ/life-threatening GPA, induce remission with glucocorticoids and rituximab. In some cases, methotrexate and mycophenolate mofetil can be substituted for rituximab. Cyclophosphamide is not preferred due to increased adverse effects, although it is equally effective.

• #10 Granulomatosis with Polyangiitis (GPA, formerly Wegener Granulomatosis) Treatment & Management: Approach Considerations, Remission Induction, Remission Maintenance

  https://emedicine.medscape.com/article/332622-treatment

  The long-term safety of rituximab in GPA was documented in a phase IV, open-label, prospective 4-year observational registry of adult patients with GPA or microscopic polyangiitis. […] Adverse effects associated with rituximab include infusion reactions, mucocutaneous reactions, increased risk of infections (including opportunistic infections such as progressive multifocal leukoencephalopathy), cytopenias (late-onset neutropenia), and malignancy. […] Historically, glucocorticoid monotherapy prolonged median survival in GPA by only 7.5 months. […] Glucocorticoids are usually given orally. If a rapid response is needed, however, such as in the case of rapidly progressive glomerulonephritis and/or alveolar hemorrhage, intravenous pulse methylprednisolone (0.5-1 g/day for 3 consecutive days) can be used and then followed by oral prednisone. […] The addition of TMP-SMZ (800/160 mg twice daily) to standard maintenance therapy may reduce the rate of relapse in GPA.

• #11 Granulomatosis with Polyangiitis (GPA) – Musculoskeletal and Connective Tissue Disorders – Merck Manual Professional Edition

  https://www.merckmanuals.com/professional/musculoskeletal-and-connective-tissue-disorders/vasculitis/granulomatosis-with-polyangiitis-gpa

  To induce remission in life- or organ-threatening GPA, high-dose corticosteroids plus either rituximab or cyclophosphamide. […] To induce remission in less severe GPA, corticosteroids and either rituximab or methotrexate. […] To maintain remission, rituximab alone or another medication such as methotrexate, azathioprine, or mycophenolate mofetil (rituximab plus another of these medications, sometimes with a low dose of a corticosteroid, if patients have multiple relapses or GPA is difficult to control). […] Treatment of granulomatosis with polyangiitis depends on the severity of disease. A multidisciplinary approach is required for multiorgan disease, often including a rheumatologist, otorhinolaryngologist, pulmonologist, and nephrologist. […] Patients who have severe life-threatening or organ-threatening manifestations (eg, alveolar hemorrhage, rapidly progressive glomerulonephritis, acute multiple mononeuropathy with motor involvement) require immediate hospital admission for treatment to induce remission.

• #12 Granulomatosis with Polyangiitis (GPA, formerly Wegener Granulomatosis) Treatment & Management: Approach Considerations, Remission Induction, Remission Maintenance

  https://emedicine.medscape.com/article/332622-treatment

  The combination of cyclophosphamide and glucocorticoids remained the recommended therapy for induction of remission in generalized/severe GPA for years. In 2011, however, the US Food and Drug Administration (FDA) approved the use of rituximab, a monoclonal antibody that targets B cells, in combination with steroids, for induction of remission in GPA (and microscopic polyangiitis). Because rituximab has been shown to be as effective as cyclophosphamide and is considered less toxic, in 2021, the American College of Rheumatology/Vasculitis Foundation guidelines conditionally recommended rituximab over cyclophosphamide for remission induction in patients with active, severe GPA. […] In general, limited disease does not require as aggressive therapy as does severe disease. Additionally, treatment recommendations are different for induction of remission and maintenance of remission.

• #13 RITUXAN® (rituximab) Treatment for GPA & MPA Patient

  https://www.rituxan.com/gpa-mpa.html

  Rituxan with glucocorticoids (GCC) is the first FDA-approved medicine for people ages 2 years and above with granulomatosis with polyangiitis (GPA) (formerly known as Wegener’s granulomatosis) and microscopic polyangiitis (MPA). […] People with Granulomatosis with Polyangiitis (GPA) (Wegeners Granulomatosis) and Microscopic Polyangiitis (MPA) ages 2 years and above: with glucocorticoids. […] Your healthcare provider will stop treatment with Rituxan if you have severe, serious, or life-threatening side effects.

• #14 Granulomatosis with Polyangiitis (GPA, formerly Wegener Granulomatosis) Treatment & Management: Approach Considerations, Remission Induction, Remission Maintenance

  https://emedicine.medscape.com/article/332622-treatment

  Current treatment recommendations in GPA depend on the severity and activity of disease. […] Generalized or severe disease generally requires aggressive therapy. Since introduced by Fauci et al in the 1970s, oral cyclophosphamide in combination with high-dose glucocorticoids (eg, prednisone 1 mg/kg/day) has been the criterion standard for induction of remission in AAV. […] Cyclophosphamide can be given either by a daily oral route or intermittent intravenous route in combination with high-dose glucocorticoids. […] Pulsed cyclophosphamide has been shown to be as effective as daily oral cyclophosphamide in inducing remission. […] Current guidelines suggest that in adults, the choice between oral and IV cyclophosphamide options should be based on patient and physician preferences, while in children, IV cyclophosphamide may be preferred to facilitate compliance and limit toxicity.

• #15 Granulomatosis with Polyangiitis (GPA, formerly Wegener Granulomatosis) Treatment & Management: Approach Considerations, Remission Induction, Remission Maintenance

  https://emedicine.medscape.com/article/332622-treatment

  Cyclophosphamide therapy is usually continued until significant disease improvement or remission occurs, typically 3-6 months. The patient is then transitioned to a less toxic medication for maintenance of remission. […] Rituximab combined with high-dose glucocorticoids represents an alternative to cyclophosphamide for induction of remission in GPA; it is the first treatment ever approved by the FDA for AAV. […] The evidence for this approval came from the RAVE (Rituximab in Antineutrophil Cytoplasmic Antibody Associated Vasculitis) trial. […] The RAVE trial, which showed the noninferiority of rituximab compared with the cyclophosphamide control group, suggested that rituximab may be better for induction treatment of relapsing disease. […] Post hoc analysis of the RAVE trial demonstrated that ANCA type may influence treatment outcome: in patients with proteinase 3 (PR3)ANCA, rates of complete remission at 6 months were 65% with rituximab versus 48% with cyclophosphamide.

• #16 Granulomatosis with Polyangiitis (GPA, formerly Wegener Granulomatosis) Treatment & Management: Approach Considerations, Remission Induction, Remission Maintenance

  https://emedicine.medscape.com/article/332622-treatment

  The combination of cyclophosphamide and glucocorticoids remained the recommended therapy for induction of remission in generalized/severe GPA for years. In 2011, however, the US Food and Drug Administration (FDA) approved the use of rituximab, a monoclonal antibody that targets B cells, in combination with steroids, for induction of remission in GPA (and microscopic polyangiitis). Because rituximab has been shown to be as effective as cyclophosphamide and is considered less toxic, in 2021, the American College of Rheumatology/Vasculitis Foundation guidelines conditionally recommended rituximab over cyclophosphamide for remission induction in patients with active, severe GPA. […] In general, limited disease does not require as aggressive therapy as does severe disease. Additionally, treatment recommendations are different for induction of remission and maintenance of remission.

• #17 Granulomatosis with Polyangiitis (GPA, formerly Wegener Granulomatosis) Guidelines: Guidelines Summary

  https://emedicine.medscape.com/article/332622-guidelines

  The American College of Rheumatology/Vasculitis Foundation has published a guideline for the management of antineutrophil cytoplasmic antibodyassociated vasculitis, including granulomatosis with polyangiitis (GPA). The guideline contains recommendations and ungraded position statements; all the recommendations are conditional, as the level of supporting evidence ranges from very low to moderate. Recommendations and position statements regarding GPA also apply to microscopic polyangiitis. […] Conditional recommendations for induction of remission in patients with active, severe disease include the following: Rituximab is preferred over cyclophosphamide. In patients with active glomerulonephritis, do not routinely add plasma exchange. In patients with alveolar hemorrhage, plasma exchange is no longer recommended. Use a reduced-dose glucocorticoid regimen rather than a standard-dose regimen.

• #18 Granulomatosis with Polyangiitis (GPA, formerly Wegener Granulomatosis) Treatment & Management: Approach Considerations, Remission Induction, Remission Maintenance

  https://emedicine.medscape.com/article/332622-treatment

  Cyclophosphamide therapy is usually continued until significant disease improvement or remission occurs, typically 3-6 months. The patient is then transitioned to a less toxic medication for maintenance of remission. […] Rituximab combined with high-dose glucocorticoids represents an alternative to cyclophosphamide for induction of remission in GPA; it is the first treatment ever approved by the FDA for AAV. […] The evidence for this approval came from the RAVE (Rituximab in Antineutrophil Cytoplasmic Antibody Associated Vasculitis) trial. […] The RAVE trial, which showed the noninferiority of rituximab compared with the cyclophosphamide control group, suggested that rituximab may be better for induction treatment of relapsing disease. […] Post hoc analysis of the RAVE trial demonstrated that ANCA type may influence treatment outcome: in patients with proteinase 3 (PR3)ANCA, rates of complete remission at 6 months were 65% with rituximab versus 48% with cyclophosphamide.

• #19 Granulomatosis with polyangiitis – Diagnosis and treatment – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/granulomatosis-with-polyangiitis/diagnosis-treatment/drc-20351093

  Once your condition is under control, you might stay on some medicines long-term. You might hear your healthcare professional call this maintenance therapy. The goal with long-term treatment is to prevent GPA from coming back, also called relapse. Medicines that can be used long-term include rituximab, methotrexate, azathioprine and mycophenolate. […] Medicines such as these can raise the risk of infection. Cyclophosphamide can cause upset stomach, diarrhea and hair loss. Your healthcare professional may prescribe other medicines to help prevent side effects from prescribed treatments. […] Plasma exchange removes the liquid portion of blood, called plasma. In most people with GPA, plasma has proteins in it that are linked with the disease. During plasma exchange, you receive fresh plasma or a protein made by the liver called albumin. Albumin helps the body make new plasma. Sometimes, plasma exchange is used to treat people who have very serious GPA. It can help the kidneys get better. Another name for this treatment is plasmapheresis.

• #20 Granulomatosis with Polyangiitis – Vasculitis Foundation

  https://vasculitisfoundation.org/education/vasculitis-types/granulomatosis-with-polyangiitis/

  Another option for those with severe disease is cyclophosphamide—a chemotherapy-type drug that blocks abnormal growth of certain cells in the body. It is used in combination with glucocorticoids. Cyclophosphamide is usually limited to a three- to six-month period, then replaced with less toxic drugs such as methotrexate, azathioprine or mycophenolate mofetil. […] Once the disease is in remission, patients will need to continue taking maintenance medications such as azathioprine, methotrexate or rituximab, to keep the disease under control. The dose of glucocorticoids is usually tapered during remission. […] A rarely used treatment option for those with very serious GPA affecting the kidneys or lungs is plasmapheresis. Plasmapheresis is a dialysis-like procedure that clears proteins from the plasma of the blood and replaces it with plasma from a donor, or with a plasma substitute.

• #21 Update on the treatment of granulomatosis with polyangiitis (Wegener’s) – PubMed

  https://pubmed.ncbi.nlm.nih.gov/22270373/

  Granulomatosis with polyangiitis (Wegener’s) (GPA), formerly known as Wegener’s granulomatosis, is a systemic vasculitis characterized by involvement of the upper airways, lungs, and kidneys. […] The current treatment of GPA is stratified based on severity. For those patients who have active but non-severe GPA and do not have contraindications, methotrexate and glucocorticoids can induce and maintain remission. […] For patients with severe disease, options include glucocorticoids combined with either cyclophosphamide or rituximab. […] In randomized trials, rituximab was found to be as effective as cyclophosphamide to induce remission of severe active GPA. […] For patients with relapsing disease who have had prior cyclophosphamide exposure, rituximab is an excellent option. […] Until such data become available, cyclophosphamide remains the agent with which there has been the greatest experience for efficacy in these settings.

• #22 Granulomatosis With Polyangiitis – StatPearls – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK557827/

  The treatment of GPA involves the use of immunosuppressive agents in a variety of combinations. Treatment is classified into 2 phases: the induction phase and the maintenance phase. Commonly used agents are cyclophosphamide, glucocorticoids, rituximab, azathioprine, methotrexate, and plasmapheresis if indicated. […] The following are key points from the 2022 EULAR recommendations for managing ANCA-associated vasculitis. For new-onset organ/life-threatening GPA (and MPA), induce remission with glucocorticoids and rituximab or cyclophosphamide. Rituximab is preferred for relapsing disease. […] For new-onset non-organ/life-threatening GPA, induce remission with glucocorticoids and rituximab. In some cases, methotrexate and mycophenolate mofetil can be substituted for rituximab. Cyclophosphamide is not preferred due to increased adverse effects, although it is equally effective.

• #23 Granulomatosis with Polyangiitis (GPA, formerly Wegener Granulomatosis) Guidelines: Guidelines Summary

  https://emedicine.medscape.com/article/332622-guidelines

  As a position statement, the guideline notes that either IV pulse or high-dose oral glucocorticoids may be prescribed as part of initial therapy. […] For induction of remission in patients with active, nonsevere disease, the guideline conditionally recommends initiating treatment with methotrexate and glucocorticoids rather than with glucocorticoids alone or glucocorticoids combined with azathioprine, mycophenolate mofetil, or trimethoprim/sulfamethoxazole. […] Conditional recommendations for remission maintenance are as follows: For patients with severe GPA whose disease has entered remission after treatment with cyclophosphamide or rituximab, use rituximab rather than methotrexate or azathioprine. For patients with GPA who are receiving rituximab for remission maintenance, provide scheduled re-dosing rather than using ANCA titers or CD19+ B-cell counts to guide re-dosing. For patients with severe GPA whose disease has entered remission after treatment with cyclophosphamide or rituximab, use methotrexate or azathioprine rather than mycophenolate mofetil or leflunomide. For patients with GPA whose disease has entered remission, use methotrexate or azathioprine in preference to trimethoprim/ sulfamethoxazole. Do not add trimethoprim/sulfamethoxazole to other therapies (eg, rituximab, azathioprine, methotrexate) for the purpose of remission maintenance. For patients receiving remission maintenance therapy with rituximab who have hypogammaglobulinemia (eg, IgG 3 g/L) and recurrent severe infections, provide immunoglobulin supplementation.

• #24 Granulomatosis With Polyangiitis – StatPearls – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK557827/

  The treatment of GPA involves the use of immunosuppressive agents in a variety of combinations. Treatment is classified into 2 phases: the induction phase and the maintenance phase. Commonly used agents are cyclophosphamide, glucocorticoids, rituximab, azathioprine, methotrexate, and plasmapheresis if indicated. […] The following are key points from the 2022 EULAR recommendations for managing ANCA-associated vasculitis. For new-onset organ/life-threatening GPA (and MPA), induce remission with glucocorticoids and rituximab or cyclophosphamide. Rituximab is preferred for relapsing disease. […] For new-onset non-organ/life-threatening GPA, induce remission with glucocorticoids and rituximab. In some cases, methotrexate and mycophenolate mofetil can be substituted for rituximab. Cyclophosphamide is not preferred due to increased adverse effects, although it is equally effective.

• #25 Granulomatosis with Polyangiitis (GPA, formerly Wegener Granulomatosis) Guidelines: Guidelines Summary

  https://emedicine.medscape.com/article/332622-guidelines

  As a position statement, the guideline notes that either IV pulse or high-dose oral glucocorticoids may be prescribed as part of initial therapy. […] For induction of remission in patients with active, nonsevere disease, the guideline conditionally recommends initiating treatment with methotrexate and glucocorticoids rather than with glucocorticoids alone or glucocorticoids combined with azathioprine, mycophenolate mofetil, or trimethoprim/sulfamethoxazole. […] Conditional recommendations for remission maintenance are as follows: For patients with severe GPA whose disease has entered remission after treatment with cyclophosphamide or rituximab, use rituximab rather than methotrexate or azathioprine. For patients with GPA who are receiving rituximab for remission maintenance, provide scheduled re-dosing rather than using ANCA titers or CD19+ B-cell counts to guide re-dosing. For patients with severe GPA whose disease has entered remission after treatment with cyclophosphamide or rituximab, use methotrexate or azathioprine rather than mycophenolate mofetil or leflunomide. For patients with GPA whose disease has entered remission, use methotrexate or azathioprine in preference to trimethoprim/ sulfamethoxazole. Do not add trimethoprim/sulfamethoxazole to other therapies (eg, rituximab, azathioprine, methotrexate) for the purpose of remission maintenance. For patients receiving remission maintenance therapy with rituximab who have hypogammaglobulinemia (eg, IgG 3 g/L) and recurrent severe infections, provide immunoglobulin supplementation.

• #26 Granulomatosis with Polyangiitis – Vasculitis Foundation

  https://vasculitisfoundation.org/education/vasculitis-types/granulomatosis-with-polyangiitis/

  In 2021, the medication avacopan (Tavneos) was approved by the FDA as an adjunctive treatment in adults for severe, active ANCA-associated vasculitis (specifically GPA and MPA) in combination with standard therapy including glucocorticoids. Avacopan (Tavneos) may help to reduce exposure to glucocorticoids. […] The medications used to treat GPA have potentially serious side effects such as lowering your body’s ability to fight infection, and potential bone loss (osteoporosis), among others. Therefore, it’s important to see your doctor for regular checkups. Medications may be prescribed to offset side effects. Infection prevention is also very important. […] GPA is a chronic disease with periods of relapse and remission. If your initial symptoms return or you develop new ones, report them to your doctor as soon as possible. Regular doctor visits and ongoing monitoring of laboratory and imaging tests are important in detecting relapses early. […] Effective treatment of GPA may require the coordinated efforts and ongoing care of a team of medical providers and specialists.

• #27 Granulomatosis With Polyangiitis – StatPearls – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK557827/

  Avacopan is an oral C5a receptor antagonist that helps block neutrophil attraction and activation. The ADVOCATE trial demonstrated that avacopan can be used to induce remission along with rituximab or cyclophosphamide, effectively reducing glucocorticoid exposure. […] Plasma exchange can be used to induce remission in patients with glomerulonephritis and a creatinine level of more than 3.39 mg/dL (300 mol/L). […] For maintenance of remission, rituximab is recommended. Azathioprine or methotrexate can also be considered, but their use should be reserved for patients with eGFR more than 60 mL/min/1.73m2. […] Maintenance therapy is initiated once remission is achieved, typically within 3 months. Patients are transitioned to maintenance therapy to avoid relapses. […] Refractory disease lacks standardized treatment recommendations. As noted above, plasmapheresis and IVIG have been used as salvage therapy.

• #28 Granulomatosis With Polyangiitis – StatPearls – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK557827/

  Avacopan is an oral C5a receptor antagonist that helps block neutrophil attraction and activation. The ADVOCATE trial demonstrated that avacopan can be used to induce remission along with rituximab or cyclophosphamide, effectively reducing glucocorticoid exposure. […] Plasma exchange can be used to induce remission in patients with glomerulonephritis and a creatinine level of more than 3.39 mg/dL (300 mol/L). […] For maintenance of remission, rituximab is recommended. Azathioprine or methotrexate can also be considered, but their use should be reserved for patients with eGFR more than 60 mL/min/1.73m2. […] Maintenance therapy is initiated once remission is achieved, typically within 3 months. Patients are transitioned to maintenance therapy to avoid relapses. […] Refractory disease lacks standardized treatment recommendations. As noted above, plasmapheresis and IVIG have been used as salvage therapy.

• #29 Granulomatosis with polyangiitis – Diagnosis and treatment – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/granulomatosis-with-polyangiitis/diagnosis-treatment/drc-20351093

  Once your condition is under control, you might stay on some medicines long-term. You might hear your healthcare professional call this maintenance therapy. The goal with long-term treatment is to prevent GPA from coming back, also called relapse. Medicines that can be used long-term include rituximab, methotrexate, azathioprine and mycophenolate. […] Medicines such as these can raise the risk of infection. Cyclophosphamide can cause upset stomach, diarrhea and hair loss. Your healthcare professional may prescribe other medicines to help prevent side effects from prescribed treatments. […] Plasma exchange removes the liquid portion of blood, called plasma. In most people with GPA, plasma has proteins in it that are linked with the disease. During plasma exchange, you receive fresh plasma or a protein made by the liver called albumin. Albumin helps the body make new plasma. Sometimes, plasma exchange is used to treat people who have very serious GPA. It can help the kidneys get better. Another name for this treatment is plasmapheresis.

• #30 Granulomatosis With Polyangiitis (GPA, formerly Wegener’s)

  https://my.clevelandclinic.org/health/diseases/granulomatosis-with-polyangiitis-formerly-wegeners-granulomatosis

  Once GPA is in remission, you’ll take milder medications to maintain remission. These typically include: […] Rituximab […] Milder immunosuppressants, such as azathioprine, methotrexate or mycophenolate mofetil. […] You’ll have ongoing testing during treatment to monitor your condition and response to the treatment. Your healthcare provider will adjust your prescription and dosage according to your response. […] Each medication comes with its own potential side effects, and they can occur at any time during your treatment. You might need to change medications to avoid or reduce the risk of certain side effects.

• #31 Granulomatosis with Polyangiitis (GPA, formerly Wegener Granulomatosis) Guidelines: Guidelines Summary

  https://emedicine.medscape.com/article/332622-guidelines

  As a position statement, the guideline notes that either IV pulse or high-dose oral glucocorticoids may be prescribed as part of initial therapy. […] For induction of remission in patients with active, nonsevere disease, the guideline conditionally recommends initiating treatment with methotrexate and glucocorticoids rather than with glucocorticoids alone or glucocorticoids combined with azathioprine, mycophenolate mofetil, or trimethoprim/sulfamethoxazole. […] Conditional recommendations for remission maintenance are as follows: For patients with severe GPA whose disease has entered remission after treatment with cyclophosphamide or rituximab, use rituximab rather than methotrexate or azathioprine. For patients with GPA who are receiving rituximab for remission maintenance, provide scheduled re-dosing rather than using ANCA titers or CD19+ B-cell counts to guide re-dosing. For patients with severe GPA whose disease has entered remission after treatment with cyclophosphamide or rituximab, use methotrexate or azathioprine rather than mycophenolate mofetil or leflunomide. For patients with GPA whose disease has entered remission, use methotrexate or azathioprine in preference to trimethoprim/ sulfamethoxazole. Do not add trimethoprim/sulfamethoxazole to other therapies (eg, rituximab, azathioprine, methotrexate) for the purpose of remission maintenance. For patients receiving remission maintenance therapy with rituximab who have hypogammaglobulinemia (eg, IgG 3 g/L) and recurrent severe infections, provide immunoglobulin supplementation.

• #32 Granulomatosis with Polyangiitis (GPA, formerly Wegener Granulomatosis) Guidelines: Guidelines Summary

  https://emedicine.medscape.com/article/332622-guidelines

  As a position statement, the guideline notes that either IV pulse or high-dose oral glucocorticoids may be prescribed as part of initial therapy. […] For induction of remission in patients with active, nonsevere disease, the guideline conditionally recommends initiating treatment with methotrexate and glucocorticoids rather than with glucocorticoids alone or glucocorticoids combined with azathioprine, mycophenolate mofetil, or trimethoprim/sulfamethoxazole. […] Conditional recommendations for remission maintenance are as follows: For patients with severe GPA whose disease has entered remission after treatment with cyclophosphamide or rituximab, use rituximab rather than methotrexate or azathioprine. For patients with GPA who are receiving rituximab for remission maintenance, provide scheduled re-dosing rather than using ANCA titers or CD19+ B-cell counts to guide re-dosing. For patients with severe GPA whose disease has entered remission after treatment with cyclophosphamide or rituximab, use methotrexate or azathioprine rather than mycophenolate mofetil or leflunomide. For patients with GPA whose disease has entered remission, use methotrexate or azathioprine in preference to trimethoprim/ sulfamethoxazole. Do not add trimethoprim/sulfamethoxazole to other therapies (eg, rituximab, azathioprine, methotrexate) for the purpose of remission maintenance. For patients receiving remission maintenance therapy with rituximab who have hypogammaglobulinemia (eg, IgG 3 g/L) and recurrent severe infections, provide immunoglobulin supplementation.

• #33 Pathology Outlines – Granulomatosis with polyangiitis (GPA)

  https://www.pathologyoutlines.com/topic/lungnontumorgranulomatosiswithpolyangiitis.html

  Usually treated with corticosteroids and cyclophosphamide with excellent prognosis […] Recent addition of rituximab (monoclonal antibody) for poorly responding cases or relapses suggested (N Engl J Med 2010;363:221) […] Methotrexate serves as effective maintenance therapy for mild / limited GPA (Am J Med 2003;114:463)

• #34 Granulomatosis with Polyangiitis – Vasculitis Foundation

  https://vasculitisfoundation.org/education/vasculitis-types/granulomatosis-with-polyangiitis/

  Another option for those with severe disease is cyclophosphamide—a chemotherapy-type drug that blocks abnormal growth of certain cells in the body. It is used in combination with glucocorticoids. Cyclophosphamide is usually limited to a three- to six-month period, then replaced with less toxic drugs such as methotrexate, azathioprine or mycophenolate mofetil. […] Once the disease is in remission, patients will need to continue taking maintenance medications such as azathioprine, methotrexate or rituximab, to keep the disease under control. The dose of glucocorticoids is usually tapered during remission. […] A rarely used treatment option for those with very serious GPA affecting the kidneys or lungs is plasmapheresis. Plasmapheresis is a dialysis-like procedure that clears proteins from the plasma of the blood and replaces it with plasma from a donor, or with a plasma substitute.

• #35

  https://link.springer.com/article/10.1007/s40620-014-0135-3

  The IMPROVE trial tested the use of mycophenolate mofetil (MMF) as a remission-maintenance agent in 156 patients with AAV. […] The rate of relapse with MMF 2,000 mg daily with dose further reduced at 12 months to 1,500 mg daily and at 18 months to 1,000 mg daily was almost double that observed with azathioprine 2 mg/kg/day, indicating that MMF at the dose used is not as effective as azathioprine for maintaining disease remission. […] Standard of care for remission-induction may not be sufficient or appropriate for all patients with GPA/MPA. […] For patients with severe (life-threatening) AAV, adjunctive plasma exchange may be considered. […] The safety data from RAVE showed no significant differences between the treatment groups in the incidence of AEs, serious AEs, or non-disease-related AEs.

• #36 Granulomatosis with Polyangiitis (GPA, formerly Wegener Granulomatosis) Guidelines: Guidelines Summary

  https://emedicine.medscape.com/article/332622-guidelines

  As a position statement, the guideline advises that the duration of remission maintenance therapy (glucocorticoid or non-glucocorticoid) should be guided by the patients clinical condition, preferences, and values. […] Conditional recommendations for patients with GPA who experience relapse with severe disease manifestations are as follows: In patients who are not receiving rituximab for remission maintenance, use rituximab rather than cyclophosphamide for remission re-induction. In patients receiving rituximab for remission maintenance, switch from rituximab to cyclophosphamide rather than giving additional rituximab. […] Conditional recommendations for patients with refractory GPA are as follows: For severe GPA that is refractory to remission induction with rituximab or cyclophosphamide, switch treatment to the other therapy rather than combining the 2 therapies. For patients with GPA that is refractory to remission induction therapy, add intravenous immunoglobulin (IVIG) to current therapy.

• #37 Granulomatosis with Polyangiitis – Vasculitis Foundation

  https://vasculitisfoundation.org/education/vasculitis-types/granulomatosis-with-polyangiitis/

  In 2021, the medication avacopan (Tavneos) was approved by the FDA as an adjunctive treatment in adults for severe, active ANCA-associated vasculitis (specifically GPA and MPA) in combination with standard therapy including glucocorticoids. Avacopan (Tavneos) may help to reduce exposure to glucocorticoids. […] The medications used to treat GPA have potentially serious side effects such as lowering your body’s ability to fight infection, and potential bone loss (osteoporosis), among others. Therefore, it’s important to see your doctor for regular checkups. Medications may be prescribed to offset side effects. Infection prevention is also very important. […] GPA is a chronic disease with periods of relapse and remission. If your initial symptoms return or you develop new ones, report them to your doctor as soon as possible. Regular doctor visits and ongoing monitoring of laboratory and imaging tests are important in detecting relapses early. […] Effective treatment of GPA may require the coordinated efforts and ongoing care of a team of medical providers and specialists.

• #38 Granulomatosis with Polyangiitis (GPA, formerly Wegener Granulomatosis) Guidelines: Guidelines Summary

  https://emedicine.medscape.com/article/332622-guidelines

  Conditional recommendations include the following: Do not dose immunosuppressive therapy on the basis of ANCA titer results alone. In patients who are receiving rituximab or cyclophosphamide, provide prophylaxis against Pneumocystis jirovecii pneumonia. For patients with GPA in remission and stage 5 chronic kidney disease, evaluate for kidney transplantation. For patients with active GPA who are unable to receive other immunomodulatory therapy, administer IVIG. […] As a position statement, the guideline notes that the optimal duration of anticoagulation is unknown for patients with GPA who experience venous thrombotic events.

• #39 Granulomatosis with Polyangiitis (GPA, formerly Wegener Granulomatosis) Treatment & Management: Approach Considerations, Remission Induction, Remission Maintenance

  https://emedicine.medscape.com/article/332622-treatment

  The mainstay of treatment for granulomatosis with polyangiitis (GPA) is a combination of corticosteroids and cytotoxic agents. Treatment should be tailored to appropriately treat GPA manifestations while minimizing long-term toxicities to the patient. Untreated generalized or severe GPA typically carries a dismal prognosis, with up to 90% of patients dying within 2 years, usually of respiratory or kidney failure. Even non-renal GPA carries a mortality rate of up to 40%. […] Outcomes for this previously fatal disease improved dramatically with the introduction in the 1970s of cyclophosphamide, which was administered in combination with corticosteroids. Approximately 90% of patients with GPA respond to cyclophosphamide, with approximately 75% experiencing complete remission. However, 30%-50% of those who initially respond experience at least one relapse, requiring another course of therapy.

• #40 New Granulomatosis with polyangiitis (Werner’s) treatments 2025 | Everyone.org

  https://everyone.org/explore/treatment/?id=45

  Initial treatment for GPA usually involves aggressive immunosuppressive therapy aimed at rapidly controlling inflammation and preventing irreversible organ damage. […] Once remission is achieved, maintenance therapy is essential to prevent disease relapse. […] Corticosteroids, such as prednisone, remain a critical component of both induction and maintenance treatments for GPA. […] Despite effective induction and maintenance therapies, relapses remain common in GPA, occurring in approximately 30-50% of patients. […] Ongoing research continues to explore novel therapeutic approaches to GPA, aiming to improve remission rates, minimize side effects, and potentially identify curative strategies. […] In addition to immunosuppressive treatments, supportive therapies play a crucial role in managing GPA complications and improving patient quality of life.

• #41 Granulomatosis with Polyangiitis (GPA, formerly Wegener Granulomatosis) Guidelines: Guidelines Summary

  https://emedicine.medscape.com/article/332622-guidelines

  As a position statement, the guideline advises that the duration of remission maintenance therapy (glucocorticoid or non-glucocorticoid) should be guided by the patients clinical condition, preferences, and values. […] Conditional recommendations for patients with GPA who experience relapse with severe disease manifestations are as follows: In patients who are not receiving rituximab for remission maintenance, use rituximab rather than cyclophosphamide for remission re-induction. In patients receiving rituximab for remission maintenance, switch from rituximab to cyclophosphamide rather than giving additional rituximab. […] Conditional recommendations for patients with refractory GPA are as follows: For severe GPA that is refractory to remission induction with rituximab or cyclophosphamide, switch treatment to the other therapy rather than combining the 2 therapies. For patients with GPA that is refractory to remission induction therapy, add intravenous immunoglobulin (IVIG) to current therapy.

• #42 Granulomatosis with polyangiitis (Wegener’s granulomatosis)

  https://patient.info/doctor/granulomatosis-with-polyangiitis-wegeners-granulomatosis-pro

  Prednisolone is given in addition to cyclophosphamide or rituximab, as it helps to increase patient survival and suppress local disease. […] Aggressive immunosuppressive therapy is required to control pulmonary and renal involvement. Plasma exchange is sometimes used as an adjunct in these circumstances. […] Once the patient is in remission, cyclophosphamide should be replaced by azathioprine or methotrexate. Leflunomide or mycophenolate may be given as alternatives if there is intolerance or lack of efficacy. […] Once the patient has been in remission for at least a year, on maintenance therapy, prednisolone can be tapered off. If the patient remains in remission six months after this, immunosuppressive treatment can be withdrawn. […] Relapses should be treated by increasing prednisolone and optimising immunosuppressive therapy. Plasma exchange may be needed. Triggers for relapse (eg, infection, malignancy, change in drug therapy) should be considered.

• #43 Granulomatosis with polyangiitis and microscopic polyangiitis: Management of disease resistant to initial therapy – UpToDate

  https://www.uptodate.com/contents/granulomatosis-with-polyangiitis-and-microscopic-polyangiitis-management-of-disease-resistant-to-initial-therapy

  Granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) are related systemic vasculitides. […] Treatment-resistant GPA or MPA refers to active disease that is organ- or life-threatening despite optimal initial immunosuppressive therapy with glucocorticoids plus either cyclophosphamide or rituximab. […] The management of resistant GPA or MPA will be reviewed here.

• #44 Granulomatosis with Polyangiitis (GPA, formerly Wegener Granulomatosis) Guidelines: Guidelines Summary

  https://emedicine.medscape.com/article/332622-guidelines

  As a position statement, the guideline advises that the duration of remission maintenance therapy (glucocorticoid or non-glucocorticoid) should be guided by the patients clinical condition, preferences, and values. […] Conditional recommendations for patients with GPA who experience relapse with severe disease manifestations are as follows: In patients who are not receiving rituximab for remission maintenance, use rituximab rather than cyclophosphamide for remission re-induction. In patients receiving rituximab for remission maintenance, switch from rituximab to cyclophosphamide rather than giving additional rituximab. […] Conditional recommendations for patients with refractory GPA are as follows: For severe GPA that is refractory to remission induction with rituximab or cyclophosphamide, switch treatment to the other therapy rather than combining the 2 therapies. For patients with GPA that is refractory to remission induction therapy, add intravenous immunoglobulin (IVIG) to current therapy.

• #45 Response to Treatment With Tofacitinib in 11 Patients With Refractory Granulomatosis With Polyangiitis | The Journal of Rheumatology

  https://www.jrheum.org/content/50/8/1088

  Granulomatosis with polyangiitis (GPA) is an antineutrophil cytoplasmic antibodyassociated vasculitis that affects mainly small-sized vessels and is characterized by upper and lower respiratory tract, kidney, eye, skin, and neurologic involvement. […] Although major improvements in the management of GPA have been made previously, some patients still experience persistently active disease despite appropriate immunosuppressive therapy and may be classified as having refractory disease. […] Tofacitinib (TOF) is a disease-modifying antirheumatic drug that inhibits Janus kinases, thereby suppressing several inflammatory mediators. […] Here, we describe the efficacy and safety of TOF treatment in 11 patients with GPA with predominantly granulomatous disease manifestations. […] All included patients gave oral and written consent to the participation in this work.

• #46 Response to Treatment With Tofacitinib in 11 Patients With Refractory Granulomatosis With Polyangiitis | The Journal of Rheumatology

  https://www.jrheum.org/content/50/8/1088

  TOF, at 5 mg doses administered twice daily, was initiated in 7 women and 4 men between May 2020 and January 2022. […] At follow-up, the median BVAS3 had decreased to 0 (range 0-7), the median CRP had decreased to 6 (range 1-57) mg/L, and the median daily PSL dose had decreased to 0 (range 0-75) mg. […] In conclusion, the findings presented in this series of 11 patients suggest that TOF may be effective and glucocorticoid-sparing in some patients with refractory GPA and granulomatous disease manifestations. […] However, based on these preliminary observations, these findings warrant confirmation in a larger group of patients with GPA in different phases of the disease.

• #47 Granulomatosis with Polyangiitis – Vasculitis Foundation

  https://vasculitisfoundation.org/education/vasculitis-types/granulomatosis-with-polyangiitis/

  In 2021, the medication avacopan (Tavneos) was approved by the FDA as an adjunctive treatment in adults for severe, active ANCA-associated vasculitis (specifically GPA and MPA) in combination with standard therapy including glucocorticoids. Avacopan (Tavneos) may help to reduce exposure to glucocorticoids. […] The medications used to treat GPA have potentially serious side effects such as lowering your body’s ability to fight infection, and potential bone loss (osteoporosis), among others. Therefore, it’s important to see your doctor for regular checkups. Medications may be prescribed to offset side effects. Infection prevention is also very important. […] GPA is a chronic disease with periods of relapse and remission. If your initial symptoms return or you develop new ones, report them to your doctor as soon as possible. Regular doctor visits and ongoing monitoring of laboratory and imaging tests are important in detecting relapses early. […] Effective treatment of GPA may require the coordinated efforts and ongoing care of a team of medical providers and specialists.

• #48 Granulomatosis with Polyangiitis (GPA, formerly Wegener Granulomatosis) Guidelines: Guidelines Summary

  https://emedicine.medscape.com/article/332622-guidelines

  Conditional recommendations include the following: Do not dose immunosuppressive therapy on the basis of ANCA titer results alone. In patients who are receiving rituximab or cyclophosphamide, provide prophylaxis against Pneumocystis jirovecii pneumonia. For patients with GPA in remission and stage 5 chronic kidney disease, evaluate for kidney transplantation. For patients with active GPA who are unable to receive other immunomodulatory therapy, administer IVIG. […] As a position statement, the guideline notes that the optimal duration of anticoagulation is unknown for patients with GPA who experience venous thrombotic events.

• #49 Predictive factors of mortality in granulomatosis with polyangiitis: A single-center study | Volume 36 – Issue 3 – September 2021 | Archives of Rheumatology

  https://archivesofrheumatology.org/full-text/1222

  All patients who were administered with CYC and RTX received additional trimethoprim/sulfamethoxazole (800/160 mg) per oral three days a week for six months for Pneumocystis jirovecii (P. jirovecii) prophylaxis. […] The overall mortality rate in our study was 16.7%. […] The presence of end-stage renal disease was found to be an independent risk factor for mortality in GPA patients. […] The CYC dose adjustment and avoidance of high-dose steroids may reduce mortality and morbidity in patients with renal insufficiency.

• #50 Granulomatosis with Polyangiitis (GPA, formerly Wegener Granulomatosis) Treatment & Management: Approach Considerations, Remission Induction, Remission Maintenance

  https://emedicine.medscape.com/article/332622-treatment

  The long-term safety of rituximab in GPA was documented in a phase IV, open-label, prospective 4-year observational registry of adult patients with GPA or microscopic polyangiitis. […] Adverse effects associated with rituximab include infusion reactions, mucocutaneous reactions, increased risk of infections (including opportunistic infections such as progressive multifocal leukoencephalopathy), cytopenias (late-onset neutropenia), and malignancy. […] Historically, glucocorticoid monotherapy prolonged median survival in GPA by only 7.5 months. […] Glucocorticoids are usually given orally. If a rapid response is needed, however, such as in the case of rapidly progressive glomerulonephritis and/or alveolar hemorrhage, intravenous pulse methylprednisolone (0.5-1 g/day for 3 consecutive days) can be used and then followed by oral prednisone. […] The addition of TMP-SMZ (800/160 mg twice daily) to standard maintenance therapy may reduce the rate of relapse in GPA.

• #51 Granulomatosis with polyangiitis – Diagnosis and treatment – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/granulomatosis-with-polyangiitis/diagnosis-treatment/drc-20351093

  Once your condition is under control, you might stay on some medicines long-term. You might hear your healthcare professional call this maintenance therapy. The goal with long-term treatment is to prevent GPA from coming back, also called relapse. Medicines that can be used long-term include rituximab, methotrexate, azathioprine and mycophenolate. […] Medicines such as these can raise the risk of infection. Cyclophosphamide can cause upset stomach, diarrhea and hair loss. Your healthcare professional may prescribe other medicines to help prevent side effects from prescribed treatments. […] Plasma exchange removes the liquid portion of blood, called plasma. In most people with GPA, plasma has proteins in it that are linked with the disease. During plasma exchange, you receive fresh plasma or a protein made by the liver called albumin. Albumin helps the body make new plasma. Sometimes, plasma exchange is used to treat people who have very serious GPA. It can help the kidneys get better. Another name for this treatment is plasmapheresis.

• #52 Granulomatosis with Polyangiitis (GPA) – Johns Hopkins Vasculitis Center

  https://www.hopkinsvasculitis.org/types-vasculitis/granulomatosis-with-polyangiitis/

  Untreated Granulomatosis with Polyangiitis is fatal. Prednisone may slow progression of the disease but by itself is insufficient to arrest the disease. Respiratory tract disease usually progresses slowly, but renal disease can progress rapidly and therefore warrants urgent evaluation and treatment. With the traditional treatment of prednisone (initiated at 1 mg/kg daily for 1 to 2 months, then tapered) and cyclophosphamide (2mg/kg daily for at least 12 months), more than 90% of patients improve and 75% remit. However, 50% of the patients who later remit also relapse, and oral daily cyclophosphamide causes serious toxicity. Short-term toxicity includes cytopenia, infection, and hemorrhagic cystitis. Long-term use of cyclophosphamide in patients with Granulomatosis with Polyangiitis more than doubles the risk of cancer overall, increases the risk of bladder cancer 33-fold and the risk of lymphoma 11-fold. Monthly intravenous cyclophosphamide appears less toxic but also less effective. Weekly, methotrexate appears to be an effective alternative for Granulomatosis with Polyangiitis that is not immediately life-threatening, and it also appears to be beneficial in maintaining remission. The role of trimethoprim-sulfamethoxazole in treating active disease is controversial, with some finding it effective for Granulomatosis with Polyangiitis limited to the respiratory tract, and others not. In patients who have achieved remission, trimethoprim-sulfamethoxazole reduces the relapse rate.

• #53 Granulomatosis with Polyangiitis (GPA, formerly Wegener Granulomatosis) Treatment & Management: Approach Considerations, Remission Induction, Remission Maintenance

  https://emedicine.medscape.com/article/332622-treatment

  The long-term safety of rituximab in GPA was documented in a phase IV, open-label, prospective 4-year observational registry of adult patients with GPA or microscopic polyangiitis. […] Adverse effects associated with rituximab include infusion reactions, mucocutaneous reactions, increased risk of infections (including opportunistic infections such as progressive multifocal leukoencephalopathy), cytopenias (late-onset neutropenia), and malignancy. […] Historically, glucocorticoid monotherapy prolonged median survival in GPA by only 7.5 months. […] Glucocorticoids are usually given orally. If a rapid response is needed, however, such as in the case of rapidly progressive glomerulonephritis and/or alveolar hemorrhage, intravenous pulse methylprednisolone (0.5-1 g/day for 3 consecutive days) can be used and then followed by oral prednisone. […] The addition of TMP-SMZ (800/160 mg twice daily) to standard maintenance therapy may reduce the rate of relapse in GPA.

• #54 Granulomatosis with polyangiitis – Diagnosis and treatment – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/granulomatosis-with-polyangiitis/diagnosis-treatment/drc-20351093

  Treatment for granulomatosis with polyangiitis (GPA) includes medicines to get the disease under control and keep it from coming back. Along with getting care from your regular healthcare professional, you’ll likely need treatment and follow-up care from various specialists. The specialists that you need depend on the organs that the disease affects. With early treatment, many people who have GPA get better and lead full lives. […] Medicines called corticosteroids help lessen the immune system response and lower inflammation of the blood vessels. Common side effects include weight gain, risk of infection and thinning of bones. […] Other medicines that lessen the immune system response include: Rituximab (Rituxan), Azathioprine (Azasan, Imuran), Mycophenolate (CellCept, Myhibbin), Methotrexate (Trexall), Cyclophosphamide, Avacopan (Tavneos).

• #55 Granulomatosis with polyangiitis Information | Mount Sinai – New York

  https://www.mountsinai.org/health-library/diseases-conditions/granulomatosis-with-polyangiitis

  Because of the potentially serious nature of GPA, you may be hospitalized. Once the diagnosis is made, you will probably be treated with high doses of glucocorticoids (such as prednisone). These are given through the vein for 3 to 5 days at the beginning of treatment. Prednisone is given along with other medicines that slow down the immune response. […] For milder disease other medicines that slow down the immune response such as methotrexate or azathioprine may be used. […] Common medicines for vasculitis include: Rituximab (Rituxan), Cyclophosphamide (Cytoxan), Methotrexate, Azathioprine (Imuran), Mycophenolate (Cellcept or Myfortic). […] These medicines are effective in severe disease, but they may cause serious side effects. Most people with GPA are treated with ongoing medicines to prevent relapse for at least 12 to 24 months. Talk to your health care provider about your treatment plan. […] Other medicines used for GPA include: Medicines to prevent bone loss caused by prednisone, Folic acid or folinic acid, if you are taking methotrexate, Antibiotics to prevent lung infections.

• #56 Granulomatosis with Polyangiitis (GPA, formerly Wegener Granulomatosis) Guidelines: Guidelines Summary

  https://emedicine.medscape.com/article/332622-guidelines

  As a position statement, the guideline notes that nasal rinses and topical nasal therapies (antibiotics, lubricants, and glucocorticoids) may be beneficial for patients with sinonasal involvement in GPA. […] Conditional recommendations include the following: For patients with GPA in remission who have nasal septal defects and/or nasal bridge collapse, reconstructive surgery, if desired by the patient, is recommended. For patients with GPA who have actively inflamed subglottic and/or endobronchial tissue with stenosis, treat with immunosuppressive therapy in preference to surgical dilation with intralesional glucocorticoid injection alone. For patients with GPA and mass lesions (eg, orbital pseudotumor or masses of the parotid glands, brain, or lungs), treat with immunosuppressive therapy in preference to surgical removal of the mass lesion with immunosuppressive therapy.

• #57 Granulomatosis with Polyangiitis (GPA) – Musculoskeletal and Connective Tissue Disorders – Merck Manual Professional Edition

  https://www.merckmanuals.com/professional/musculoskeletal-and-connective-tissue-disorders/vasculitis/granulomatosis-with-polyangiitis-gpa

  Irrigation of sinuses with saline, with or without mupirocin 2% nasal ointment, helps minimize crusting and secondary staphylococcal infections. […] Treatment of subglottic stenosis is difficult. […] Systemic immunosuppressants may not be effective. […] Kidney transplantation has been successful; the risk of relapse after transplantation is reduced compared with maintenance dialysis treatment (possibly due to use of immunosuppressants to prevent rejection).

• #58 Granulomatosis with Polyangiitis (GPA, formerly Wegener Granulomatosis) Guidelines: Guidelines Summary

  https://emedicine.medscape.com/article/332622-guidelines

  As a position statement, the guideline notes that nasal rinses and topical nasal therapies (antibiotics, lubricants, and glucocorticoids) may be beneficial for patients with sinonasal involvement in GPA. […] Conditional recommendations include the following: For patients with GPA in remission who have nasal septal defects and/or nasal bridge collapse, reconstructive surgery, if desired by the patient, is recommended. For patients with GPA who have actively inflamed subglottic and/or endobronchial tissue with stenosis, treat with immunosuppressive therapy in preference to surgical dilation with intralesional glucocorticoid injection alone. For patients with GPA and mass lesions (eg, orbital pseudotumor or masses of the parotid glands, brain, or lungs), treat with immunosuppressive therapy in preference to surgical removal of the mass lesion with immunosuppressive therapy.

• #59 Granulomatosis with Polyangiitis (GPA) – Musculoskeletal and Connective Tissue Disorders – Merck Manual Professional Edition

  https://www.merckmanuals.com/professional/musculoskeletal-and-connective-tissue-disorders/vasculitis/granulomatosis-with-polyangiitis-gpa

  Irrigation of sinuses with saline, with or without mupirocin 2% nasal ointment, helps minimize crusting and secondary staphylococcal infections. […] Treatment of subglottic stenosis is difficult. […] Systemic immunosuppressants may not be effective. […] Kidney transplantation has been successful; the risk of relapse after transplantation is reduced compared with maintenance dialysis treatment (possibly due to use of immunosuppressants to prevent rejection).

• #60 Granulomatosis with Polyangiitis (GPA, formerly Wegener Granulomatosis) Guidelines: Guidelines Summary

  https://emedicine.medscape.com/article/332622-guidelines

  As a position statement, the guideline notes that nasal rinses and topical nasal therapies (antibiotics, lubricants, and glucocorticoids) may be beneficial for patients with sinonasal involvement in GPA. […] Conditional recommendations include the following: For patients with GPA in remission who have nasal septal defects and/or nasal bridge collapse, reconstructive surgery, if desired by the patient, is recommended. For patients with GPA who have actively inflamed subglottic and/or endobronchial tissue with stenosis, treat with immunosuppressive therapy in preference to surgical dilation with intralesional glucocorticoid injection alone. For patients with GPA and mass lesions (eg, orbital pseudotumor or masses of the parotid glands, brain, or lungs), treat with immunosuppressive therapy in preference to surgical removal of the mass lesion with immunosuppressive therapy.

• #61 Granulomatosis with Polyangiitis (GPA) – EyeWiki

  https://eyewiki.org/Granulomatosis_with_Polyangiitis_(GPA)

  However, treatment with cyclophosphamide in place of methotrexate should be initiated if it is determined that the patients disease is more aggressive, if methotrexate is ineffective, or if proteinuria is of serious concern. […] Alternatively, rituximab can be used in place of cyclophosphamide if there are indications that a patient cannot tolerate methotrexate or cyclophosphamide. […] For patients with ocular manifestations of GPA, rituximab should be considered. In a recent study, rituximab was shown to effectively induce remission in treatment-refractory ocular manifestations of GPA. […] In patients presenting with severe or particularly aggressive disease, or with advanced renal involvement, combination therapy of glucocorticoids, cyclophosphamide or rituximab, and plasma exchange is advised.

• #62 Successful Treatment Strategies in Granulomatosis With Polyangiitis-Associated Peripheral Ulcerative Keratitis. | Harvard Medical School Department of Ophthalmology

  https://eye.hms.harvard.edu/publications/successful-treatment-strategies-granulomatosis-polyangiitis-associated-peripheral

  PURPOSE: Management of granulomatosis with polyangiitis (GPA)-associated peripheral ulcerative keratitis (PUK) is challenging and lacks definite guidelines. We aimed to summarize our treatment and outcome experience with patients with GPA-PUK. […] RESULTS: There were 16 patients who started treatment with a mean duration follow-up of 64 months (range: 12-110 mo). Rituximab and cyclophosphamide, either alone or in combination with other agents, were the most successful agents in controlling inflammation. Rituximab was administered in 11 patients with remission being achieved in all. Cyclophosphamide successfully controlled inflammation in 50% (5/10). […] CONCLUSIONS: Rituximab achieved a high rate of disease control in PUK patients with GPA and is the preferred agent in halting disease progression.

• #63 Granulomatosis with Polyangiitis (GPA, formerly Wegener Granulomatosis) Guidelines: Guidelines Summary

  https://emedicine.medscape.com/article/332622-guidelines

  Conditional recommendations include the following: Do not dose immunosuppressive therapy on the basis of ANCA titer results alone. In patients who are receiving rituximab or cyclophosphamide, provide prophylaxis against Pneumocystis jirovecii pneumonia. For patients with GPA in remission and stage 5 chronic kidney disease, evaluate for kidney transplantation. For patients with active GPA who are unable to receive other immunomodulatory therapy, administer IVIG. […] As a position statement, the guideline notes that the optimal duration of anticoagulation is unknown for patients with GPA who experience venous thrombotic events.

• #64 Granulomatosis with Polyangiitis (GPA) – Musculoskeletal and Connective Tissue Disorders – Merck Manual Professional Edition

  https://www.merckmanuals.com/professional/musculoskeletal-and-connective-tissue-disorders/vasculitis/granulomatosis-with-polyangiitis-gpa

  Irrigation of sinuses with saline, with or without mupirocin 2% nasal ointment, helps minimize crusting and secondary staphylococcal infections. […] Treatment of subglottic stenosis is difficult. […] Systemic immunosuppressants may not be effective. […] Kidney transplantation has been successful; the risk of relapse after transplantation is reduced compared with maintenance dialysis treatment (possibly due to use of immunosuppressants to prevent rejection).

• #65 Granulomatosis with Polyangiitis – Vasculitis Foundation

  https://vasculitisfoundation.org/education/vasculitis-types/granulomatosis-with-polyangiitis/

  In 2021, the medication avacopan (Tavneos) was approved by the FDA as an adjunctive treatment in adults for severe, active ANCA-associated vasculitis (specifically GPA and MPA) in combination with standard therapy including glucocorticoids. Avacopan (Tavneos) may help to reduce exposure to glucocorticoids. […] The medications used to treat GPA have potentially serious side effects such as lowering your body’s ability to fight infection, and potential bone loss (osteoporosis), among others. Therefore, it’s important to see your doctor for regular checkups. Medications may be prescribed to offset side effects. Infection prevention is also very important. […] GPA is a chronic disease with periods of relapse and remission. If your initial symptoms return or you develop new ones, report them to your doctor as soon as possible. Regular doctor visits and ongoing monitoring of laboratory and imaging tests are important in detecting relapses early. […] Effective treatment of GPA may require the coordinated efforts and ongoing care of a team of medical providers and specialists.

• #66 Granulomatosis with Polyangiitis (GPA) – Musculoskeletal and Connective Tissue Disorders – Merck Manual Professional Edition

  https://www.merckmanuals.com/professional/musculoskeletal-and-connective-tissue-disorders/vasculitis/granulomatosis-with-polyangiitis-gpa

  To induce remission in life- or organ-threatening GPA, high-dose corticosteroids plus either rituximab or cyclophosphamide. […] To induce remission in less severe GPA, corticosteroids and either rituximab or methotrexate. […] To maintain remission, rituximab alone or another medication such as methotrexate, azathioprine, or mycophenolate mofetil (rituximab plus another of these medications, sometimes with a low dose of a corticosteroid, if patients have multiple relapses or GPA is difficult to control). […] Treatment of granulomatosis with polyangiitis depends on the severity of disease. A multidisciplinary approach is required for multiorgan disease, often including a rheumatologist, otorhinolaryngologist, pulmonologist, and nephrologist. […] Patients who have severe life-threatening or organ-threatening manifestations (eg, alveolar hemorrhage, rapidly progressive glomerulonephritis, acute multiple mononeuropathy with motor involvement) require immediate hospital admission for treatment to induce remission.

• #67 Granulomatosis with Polyangiitis | Conditions & Treatments | UR Medicine

  https://www.urmc.rochester.edu/conditions-and-treatments/granulomatosis-with-polyangiitis

  Since this disease affects many parts of the body, more than one specialist may be involved in diagnosing and managing your illness. Specialists may include a pulmonologist (lungs), nephrologist (kidneys) and rheumatologist (autoimmune diseases). […] Common medicines used in treatment include: […] Corticosteroids. This helps reduce inflammation. […] Rituximab. This is an antibody against certain immune cells (B-cells) that can the autoimmune problem in GPA. […] Cyclophosphamide. This is an immunosuppressive medication. […] GPA may come back even after successful treatment. Continue to follow up with your healthcare provider, even when you are in remission.

• #68 ENT manifestations of Granulomatosis with polyangiitis

  https://www.oaepublish.com/articles/2574-1209.2021.52

  Long-term management of airway narrowing utilizes a combination of endoscopic and open surgery. Endoscopic laryngeal dilation with rigid or balloon dilators can achieve a satisfactory outcome. […] A multidisciplinary approach for the management of cases with GPA is mandatory for proper early diagnosis and treatment. Although immunosuppressive therapy is the keystone of management of GPA, local therapies do improve the patient’s quality of life and – in some cases – are life-saving.

• #69 Granulomatosis with Polyangiitis (GPA, formerly Wegener Granulomatosis) Treatment & Management: Approach Considerations, Remission Induction, Remission Maintenance

  https://emedicine.medscape.com/article/332622-treatment

  The mainstay of treatment for granulomatosis with polyangiitis (GPA) is a combination of corticosteroids and cytotoxic agents. Treatment should be tailored to appropriately treat GPA manifestations while minimizing long-term toxicities to the patient. Untreated generalized or severe GPA typically carries a dismal prognosis, with up to 90% of patients dying within 2 years, usually of respiratory or kidney failure. Even non-renal GPA carries a mortality rate of up to 40%. […] Outcomes for this previously fatal disease improved dramatically with the introduction in the 1970s of cyclophosphamide, which was administered in combination with corticosteroids. Approximately 90% of patients with GPA respond to cyclophosphamide, with approximately 75% experiencing complete remission. However, 30%-50% of those who initially respond experience at least one relapse, requiring another course of therapy.

• #70 Granulomatosis with Polyangiitis (GPA) – Johns Hopkins Vasculitis Center

  https://www.hopkinsvasculitis.org/types-vasculitis/granulomatosis-with-polyangiitis/

  Until the 1970s, Granulomatosis with Polyangiitis was nearly always a fatal condition. The use of prednisone and other steroids helped prolong patients lives, but most patients eventually succumbed to the disease within a few months or years. The first use of cyclophosphamide in the late 1960s began to change the terrible prognosis of this disease. Using the combination of cyclophosphamide and prednisone, more than 90% of patients with severe disease respond to treatment, and 75% are able to achieve disease remissions. Unfortunately, Granulomatosis with Polyangiitis is a disease in which relapses frequently occur. Approximately half of all patients who achieve disease remissions eventually suffer recurrences (flares). Flares of Granulomatosis with Polyangiitis are usually responsive to the same treatment that induced remission, but sometimes intensification of treatment (for example, changing to a more powerful medication) is required.

• #71 Granulomatosis with Polyangiitis (GPA) – Johns Hopkins Vasculitis Center

  https://www.hopkinsvasculitis.org/types-vasculitis/granulomatosis-with-polyangiitis/

  Until the 1970s, Granulomatosis with Polyangiitis was nearly always a fatal condition. The use of prednisone and other steroids helped prolong patients lives, but most patients eventually succumbed to the disease within a few months or years. The first use of cyclophosphamide in the late 1960s began to change the terrible prognosis of this disease. Using the combination of cyclophosphamide and prednisone, more than 90% of patients with severe disease respond to treatment, and 75% are able to achieve disease remissions. Unfortunately, Granulomatosis with Polyangiitis is a disease in which relapses frequently occur. Approximately half of all patients who achieve disease remissions eventually suffer recurrences (flares). Flares of Granulomatosis with Polyangiitis are usually responsive to the same treatment that induced remission, but sometimes intensification of treatment (for example, changing to a more powerful medication) is required.

• #72 Granulomatosis with polyangiitis (GPA): Symptoms, causes, and more

  https://www.medicalnewstoday.com/articles/187807

  Before steroid and cyclophosphamide treatment became available, 82 percent of patients with GPA died within the first year, and average survival was 5 months. Progress made in the last 50 years means that 90 percent of patients will survive, and some can expect another 20 years without remission. […] Rituximab, or Rituxan, may be used. This drug which was originally designed to treat non-Hodgkins lymphoma, a type of cancer. Later, it was approved for the treatment of rheumatoid arthritis (RA). Rituximab reduces the number of B cells in the body. B cells are involved in inflammation. If standard treatments are not effective, some doctors may prescribe Rituximab. […] Many drugs used to treat this condition weaken the patients immune system, so it is important to monitor the patient. A lower immune system is less able to fight off infection. […] Some patients may need surgery. If kidney failure occurs, the doctor may recommend a kidney transplant.

• #73 Granulomatosis with polyangiitis (GPA): Symptoms, causes, and more

  https://www.medicalnewstoday.com/articles/187807

  GPA requires long-term immunosuppression. Some patients die due to the toxicity of the treatment. […] Treatment for GPA is usually divided into two stages: The induction of disease remission, which involves getting rid of all the signs and symptoms. Maintenance of disease remission, to prevent a recurrence. […] Early diagnosis and treatment improve the patients chances of going into remission within months. Some patients may require longer. […] Corticosteroids, such as prednisone, may be prescribed for initial signs and symptoms. In a few cases, this is the only medication needed. […] Other immunosuppressive drugs, such as cyclophosphamide (Cytoxan), azathioprine (Imuran) or methotrexate (Rheumatrex) are also prescribed in most cases. The aim is to stop the bodys immune system from overreacting.

• #74 Predictive factors of mortality in granulomatosis with polyangiitis: A single-center study | Volume 36 – Issue 3 – September 2021 | Archives of Rheumatology

  https://archivesofrheumatology.org/full-text/1222

  The aim of this study was to identify predictors of mortality in granulomatosis with polyangiitis (GPA) patients and to seek the ways of improving survival in GPA patients. […] The presence of dialysis-requiring renal damage is the most important risk factor for mortality in GPA patients. These patients should be followed more closely and carefully to improve survival. […] The major risk for GPA patients is the adverse events associated with the treatment, rather than those associated with active vasculitis. […] Immunosuppressive drugs exerted no effect on mortality, and the most common causes of death were infections (50%). […] The CYC and corticosteroid were administered in the remission induction therapy. […] For the maintenance therapy, azathioprine (AZA) (at a dose of 2 mg/kg/day during the first 12 months, 1.5 mg/kg/day at 12 to 18 months, and 1 mg/kg/day after 18 months), methotrexate (MTX; 15 to 20 mg/week), mycophenolate mofetil (2 g/day), or RTX were administered.

• #75 Predictive factors of mortality in granulomatosis with polyangiitis: A single-center study | Volume 36 – Issue 3 – September 2021 | Archives of Rheumatology

  https://archivesofrheumatology.org/full-text/1222

  The aim of this study was to identify predictors of mortality in granulomatosis with polyangiitis (GPA) patients and to seek the ways of improving survival in GPA patients. […] The presence of dialysis-requiring renal damage is the most important risk factor for mortality in GPA patients. These patients should be followed more closely and carefully to improve survival. […] The major risk for GPA patients is the adverse events associated with the treatment, rather than those associated with active vasculitis. […] Immunosuppressive drugs exerted no effect on mortality, and the most common causes of death were infections (50%). […] The CYC and corticosteroid were administered in the remission induction therapy. […] For the maintenance therapy, azathioprine (AZA) (at a dose of 2 mg/kg/day during the first 12 months, 1.5 mg/kg/day at 12 to 18 months, and 1 mg/kg/day after 18 months), methotrexate (MTX; 15 to 20 mg/week), mycophenolate mofetil (2 g/day), or RTX were administered.

• #76 Granulomatosis with Polyangiitis – Vasculitis Foundation

  https://vasculitisfoundation.org/education/vasculitis-types/granulomatosis-with-polyangiitis/

  Granulomatosis with polyangiitis (GPA) is a potentially serious but treatable disease. Glucocorticoids such as prednisone are used in combination with other medications that suppress the immune system to control inflammation. Even with effective treatment, relapse can occur, so ongoing medical follow-up is usually necessary. […] The choice of treatment for GPA depends on the organs affected and disease severity. Patients with milder disease are commonly prescribed glucocorticoids such as prednisone in combination with another medication such as methotrexate to control inflammation and induce remission of disease. […] Patients with severe disease may be prescribed the biologic drug rituximab, used in conjunction with glucocorticoids. Rituximab was approved in 2011 by the U.S. Food and Drug Administration (FDA) for the treatment of GPA and another form of vasculitis, microscopic polyangiitis (MPA).

• #77 Granulomatosis With Polyangiitis – StatPearls – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK557827/

  The treatment of GPA involves the use of immunosuppressive agents in a variety of combinations. Treatment is classified into 2 phases: the induction phase and the maintenance phase. Commonly used agents are cyclophosphamide, glucocorticoids, rituximab, azathioprine, methotrexate, and plasmapheresis if indicated. […] The following are key points from the 2022 EULAR recommendations for managing ANCA-associated vasculitis. For new-onset organ/life-threatening GPA (and MPA), induce remission with glucocorticoids and rituximab or cyclophosphamide. Rituximab is preferred for relapsing disease. […] For new-onset non-organ/life-threatening GPA, induce remission with glucocorticoids and rituximab. In some cases, methotrexate and mycophenolate mofetil can be substituted for rituximab. Cyclophosphamide is not preferred due to increased adverse effects, although it is equally effective.

• #78 Granulomatosis with Polyangiitis – Vasculitis Foundation

  https://vasculitisfoundation.org/education/vasculitis-types/granulomatosis-with-polyangiitis/

  In 2021, the medication avacopan (Tavneos) was approved by the FDA as an adjunctive treatment in adults for severe, active ANCA-associated vasculitis (specifically GPA and MPA) in combination with standard therapy including glucocorticoids. Avacopan (Tavneos) may help to reduce exposure to glucocorticoids. […] The medications used to treat GPA have potentially serious side effects such as lowering your body’s ability to fight infection, and potential bone loss (osteoporosis), among others. Therefore, it’s important to see your doctor for regular checkups. Medications may be prescribed to offset side effects. Infection prevention is also very important. […] GPA is a chronic disease with periods of relapse and remission. If your initial symptoms return or you develop new ones, report them to your doctor as soon as possible. Regular doctor visits and ongoing monitoring of laboratory and imaging tests are important in detecting relapses early. […] Effective treatment of GPA may require the coordinated efforts and ongoing care of a team of medical providers and specialists.

• #79 Granulomatosis with polyangiitis – Symptoms and causes – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/granulomatosis-with-polyangiitis/symptoms-causes/syc-20351088

  It’s important for healthcare professionals to find and treat GPA as soon as possible. Early treatment can help people live full lives. Without treatment, the condition can lead to organ damage that sometimes is fatal. […] The disease can become worse quickly. Without treatment, it can lead to other serious health conditions called complications. That’s why it’s important for a healthcare professional to find it and start treatment early.

• #80 New Granulomatosis with polyangiitis (Werner’s) treatments 2025 | Everyone.org

  https://everyone.org/explore/treatment/?id=45

  With appropriate treatment, the long-term prognosis for GPA patients has significantly improved over recent decades. […] In summary, while there is currently no definitive cure for Granulomatosis with Polyangiitis (Wegener’s), modern therapeutic approaches have significantly improved patient outcomes, enabling many individuals to achieve sustained remission and maintain good quality of life.

Zobacz więcej